1 **Supplementary Material**

2 **Figure S1.** Urinary creatinine concentrations according to vancomycin exposure measures.

3

B.

Vancomycin Cmax (mcg/mL)

4

C.

Vancomycin Cmin (mcg/mL)

5

6   **Figure legend:** All non-parametric correlations P > 0.05. Panels: A) urinary creatinine v. $AUC_{0-24\ h}$

7   (μg*hr/L); B) urinary creatinine v. $Cmax_{0-24\ h}$ (μg/mL); C) urinary creatinine v. $Cmin_{0-24\ h}$ (μg/mL).

8   **Table S1.** Summary of sensitive and traditional urinary AKI biomarkers according to vancomycin exposure group and protocol duration

Experimental condition	One-day protocol			Three-day protocol		
	Control	Vancomycin	P-value	Control	Vancomycin	P-value
Number of animals (n/N)	5/52	22/52		5/52	20/52	
Clusterin (ng/mL), median (IQR)	225 (205-243)	291 (191-436), n=21	0.31	245 (208-344)	338 (155-619), n=17	0.72
Cystatin C (ng/mL), mean±SD	2.0±0.77	3.1±1.4, n=21	0.10	3.5±0.63	2.8±1.4, n=17	0.26
KIM-1 (ng/mL), median (IQR)	0.46 (0.28-0.59)	0.83 (0.52-1.34), n=21	0.02	1.21 (0.59-1.23)	1.40 (0.40-7.37), n=17	0.72
Osteopontin (ng/mL), median (IQR)	0.03 (0.03-0.03)	0.06 (0.05-0.13), n=21	0.001	0.04 (0.04-0.16)	0.07 (0.08-0.16), n=17	0.15
Lipocalin-2/NGAL (ng/mL), mean±SD	6.1±3.4	10.8±4.6, n=21	0.04	13.7±2.4	12.2±5.6, n=17	0.55
Urinary Creatinine (mg/dL), median (IQR)	—	0 (0-0)	—	0.007 (0.002 - 0.018)	0 (0-0.0005)	0.62

9   **Table legend:** Urinary endpoints stratified by experimental condition (i.e., vancomycin or saline control) and protocol duration (1 or 3 days).

10   **Abbreviations:** IQR, interquartile range; KIM-1, kidney injury molecule 1, SD, standard deviation